Replies to post #186855 on Biotech Values

[DewDiligence]

AGTC—Another key question is why Genzyme walked away from AGTC and their tech before. Does that raise questions in general about their tech and pipeline or was it just something specific to one drug…?

Genzyme’s license from AGTC related to only one program: gene therapy for wet AMD.

…[or] a move related in part to Sanofi/REGN's close ties?

Possibly. SNY’s close partnership with REGN could have played a role, but the discontinued AMD program had other problems, IMO.

AGTC’s AAV-vector technology has improved in the eight years since the AMD deal was struck with Genzyme, so I don’t consider the Genzyme history a significant blemish for AGTC.